SHL Telemedicine Ltd. (SHLT)
NASDAQ: SHLT · Real-Time Price · USD
2.976
+0.246 (9.01%)
Nov 7, 2024, 4:00 PM EST - Market closed
SHL Telemedicine Revenue
SHL Telemedicine had revenue of $27.87M in the half year ending June 30, 2024, a decrease of -9.81%. This brings the company's revenue in the last twelve months to $55.94M, down -2.04% year-over-year. In the year 2023, SHL Telemedicine had annual revenue of $57.08M, down -3.26%.
Revenue (ttm)
$55.94M
Revenue Growth
-2.04%
P/S Ratio
n/a
Revenue / Employee
$95,950
Employees
583
Market Cap
46.95M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 57.08M | -1.92M | -3.26% |
Dec 31, 2022 | 59.00M | 9.42M | 18.99% |
Dec 31, 2021 | 49.58M | 9.42M | 23.45% |
Dec 31, 2020 | 40.16M | -1.72M | -4.11% |
Dec 31, 2019 | 41.88M | -6.98M | -14.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Exagen | 56.66M |
Allurion Technologies | 47.59M |
Carisma Therapeutics | 20.71M |
Accelerate Diagnostics | 12.23M |
VYNE Therapeutics | 486.00K |
Daxor | 154.21K |
Eyenovia | 31.41K |
Incannex Healthcare | 12.00K |
SHLT News
- 3 months ago - SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine - Business Wire
- 5 months ago - SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity - Business Wire
- 6 months ago - SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test - Business Wire
- 6 months ago - SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch - Business Wire
- 7 months ago - SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones - Business Wire
- 7 months ago - Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care - Business Wire
- 7 months ago - SHL Telemedicine's SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment - Business Wire
- 7 months ago - SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023 - Business Wire